Dechra Veterinary Products’ new intramuscular clodronic acid injection, Osphos, is the UK’s only licensed product for the control of clinical signs of navicular syndrome in horses.

The company says the product will change the way equine vets tackle chronic lameness caused by the bone resorptive processes associated with navicular syndrome.

Clinical trials of Osphos showed 74.7% of horses experienced improvement by at least one lameness grade at 56 days after treatment.

Dechra brand manager Emma Jennings said: “Osphos contains the bisphosphonate clodronic acid, which inhibits resorption in the navicular bone by binding to hydroxyapatite crystals and by direct cellular effects on osteoclasts.

“We are delighted with the results of the trials, which proved it is effective at six months post-treatment.

“We’re looking forward to being able to support equine vets, vet nurses and practices by providing it for horses.”

Studies have revealed mild transient colic was seen following 1.6% of treatments.

Osphos 60mg/ml solution for injection for horses is available now.

View your activity >

Leave a Reply

Be the First to Comment!

Notify of